Clinical Trials Logo

Filter by:
NCT ID: NCT02984150 Completed - Healthy Volunteers Clinical Trials

Effect of Intragastric Administration of Fatty Acids on Generalized Reward Sensitivity

Start date: November 2014
Phase: N/A
Study type: Interventional

This study aim to investigate the influence of intragastrically infused fatty acid on the generalization of responses to reward within the food domain and between financial and sexual domains.

NCT ID: NCT02983396 Completed - Chest Pain Clinical Trials

The Accuracy of the Mini RELF Device for the Diagnosis of an Acute Coronary Artery Occlusion.

RELF IIa
Start date: November 18, 2016
Phase: N/A
Study type: Interventional

Patient delay in seeking medical attendance for symptoms of acute ST elevation myocardial infarction (STEMI) is the major obstacle to reduce the current mortality from acute coronary syndromes. The Mini RELF device is a hand held self applicable device intended to detect on an individual basis an elevation of the ST segment that is indicative for an acute coronary occlusion. The investigators aim to evaluate the accuracy of Mini RELF device when it is self-applied on a daily basis by patients with coronary artery disease.

NCT ID: NCT02983045 Completed - Gastric Cancer Clinical Trials

A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors

PIVOT-02
Start date: December 19, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

In this four-part study, NKTR-214 was administered in combination with nivolumab and with/without other anticancer therapies. Part 1 considered escalating doublet (NKTR 214 + nivolumab) doses to determine the RP2D. Part 2 considered dose expansion cohorts for the doublet (NKTR 214 + nivolumab ± chemotherapy). Part 3 was schedule-finding for a triplet therapy (NKTR 214 + nivolumab + ipilimumab). Part 4 dose expansion for the triplet (NKTR 214 + nivolumab + ipilimumab) was planned to further assess the efficacy of the RP2D triplet combination at dosing schedules from Part 3.

NCT ID: NCT02982811 Completed - Aged Clinical Trials

Intelligent Activity-based Client-centred Training

i-ACT
Start date: March 1, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether additional therapy with i-ACT system is effective in the training of functional skills in persons with central neurological diseases (e.g. multiple sclerosis, stroke, spinal cord injury, etc.).

NCT ID: NCT02982616 Completed - Healthy Volunteers Clinical Trials

Influence of Intragastric Fatty Acid Infusion on Behavioral Responses to Positive Emotion Induction in Healthy Subjects

Start date: August 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to test whether intragastrically infused fatty acid will interact with positive emotion induction and if this effect is mediated by gut hormones.

NCT ID: NCT02982122 Completed - Clinical trials for Brain Injuries, Traumatic

CPPopt Guided Therapy: Assessment of Target Effectiveness

COGITATE
Start date: March 1, 2018
Phase: N/A
Study type: Interventional

Despite improvements in management, mortality in severe traumatic brain injury (TBI) remains 25% and only 40% of patients survive without major handicap. Medical/surgical interventions aim to maintain adequate brain perfusion, which is critically dependent on cerebral perfusion pressure (CPP); calculated as the difference between mean arterial pressure (MAP) and intracranial pressure (ICP). Current guidelines aim for a CPP above 50 mmHg, based on population means. However, this 'one size fits all' approach is flawed, because the relation between CPP and brain perfusion varies between individuals. Further, this approach takes no account of autoregulation, a key protective mechanism that maintains cerebral perfusion despite CPP fluctuations. Autoregulation is variably preserved following TBI, and there are large between patient variances in the 'optimal' CPP (CPPopt) at which autoregulation operates best. Individual CPPopt can be retrieved automatically by plotting autoregulation data against the CPP over a certain time window. The investigators have shown that maintenance of CPP close to CPPopt is associated with improved outcomes. These data pose the hypothesis that optimisation of management in individuals may be achieved by using the zone of optimal autoregulation as a basis for defining individualised CPP targets. The investigators propose, together with collaborators in the CPPopt study group (Maastricht, Cambridge, Leuven and Aachen) to set up a pilot (multicenter) feasibility study to develop a protocol for a definitive outcome randomized controlled trial (RCT). This study aims to develop protocols for CPPopt guided critical care, and show that they maintain patients closer to their optimum perfusion levels than standard protocols which keep above a population CPP threshold of 60 mmHg. Hence, the main objective is to offer clinicians monitoring and therapy algorithms that achieve individualized optimal CPPopt targets and potentially improve TBI outcome.

NCT ID: NCT02982057 Completed - STEMI Clinical Trials

Non Culprit Lesion Study

Start date: January 2015
Phase: Phase 3
Study type: Interventional

The aim of the present study is to compare the evolution of non culprit lesions after treatment by BVS versus optimal medical therapy at 2-years follow- up

NCT ID: NCT02981342 Completed - Clinical trials for Pancreatic Ductal Adenocarcinoma

A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma

Start date: January 12, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of abemaciclib alone and in combination with other drugs versus standard of care in participants with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).

NCT ID: NCT02979782 Completed - Delirium Clinical Trials

Neurological Outcome After Minimal Invasive Coronary Artery Bypass Graft

NOMICS
Start date: December 2016
Phase:
Study type: Observational

Primary objectives: Assessment of the incidence of postoperative cognitive dysfunction (POCD), cerebrovascular accident (CVA), and delirium after minimal invasive coronary artery bypass grafting (Endo-CABG). Secondary objectives: - Quality of life, three months after endo-CABG - Patient satisfaction with endo-CABG and the tests performed - The influence of various demographic and peri-operative variables on neurological outcome after endo-CABG - Incidence of fear and depression, 3 months after endo-CABG

NCT ID: NCT02979431 Completed - Clinical trials for Respiratory Syncytial Virus Lower Respiratory Tract Infection

Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection

Respire
Start date: January 11, 2017
Phase: Phase 2
Study type: Interventional

The primary objective is to evaluate the anti-viral effect and safety of different doses of inhaled ALX-0171 in subjects hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection (RSV LRTI). The secondary objective is to evaluate the clinical activity, pharmacokinetic (PK) properties, pharmacodynamic (PD) effect and immunogenicity of different doses of inhaled ALX-0171.